Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database
Mai Thi Tuyet Kieu, Duc Quang Tran, Anh Thi Phuong Le, Ha Thi Nguyen, Minh Cong Nguyen · 2026
Read Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database by Mai Thi Tuyet Kieu, Duc Quang Tran, Anh Thi Phuong Le, Ha Thi Nguyen, Minh Cong Nguyen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13222581.txt.
Description
Mai Thi Tuyet Kieu and co-authors analyze cancer medicine consumption in Vietnam from 2019 to 2023, in a 2026 cross-sectional study of national procurement data. Every bidding package and contract from the Drug Administration of Vietnam fed the analysis. Spending was sorted by technical group, chemical class, procurement level, manufacturing origin, and administration route.
Total consumption reached about 1.4 billion dollars across the five years, dipping sharply to 2022 before peaking in 2023. Targeted therapies took the largest share throughout, followed by chemotherapy, with immunotherapy smaller but growing. Originator and top-tier generic products dominated spending. Mean price per milligram fell over time, and national centralized bidding generally beat regional buying on efficiency.
Catalog record
| CREATOR | Mai Thi Tuyet Kieu, Duc Quang Tran, Anh Thi Phuong Le, Ha Thi Nguyen, Minh Cong Nguyen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |